A first in man phase I trial of the oral immunomodulator, indoximod, combined with docetaxel in patients with metastatic solid tumors

Soliman, Hatem H., Jackson, Erica, Neuger, Tony, Dees, E. Claire, Harvey, R. Donald, Han, Hyo, Ismail-Khan, Roohi, Minton, Susan +4 more·2014·Oncotarget
DOI 10.18632/oncotarget.2357

Cited by (180)

Items 101–180 of 180

  1. Tackling Immune Targets for Breast Cancer: Beyond PD-1/PD-L1 Axis
    Yasser Tabana, Isobel Okoye, Arno G. Siraki, Shokrollah Elahi, Khaled Barakat · 2021 · Frontiers in Oncology
  2. Modulating Tumor Immunology by Inhibiting Indoleamine 2,3-Dioxygenase (IDO): Recent Developments and First Clinical Experiences
    Diwakar Davar, Nathan Bahary · 2018 · Targeted Oncology
  3. Update on targeted therapies for advanced non-small cell lung cancer: nivolumab in context
    Alexander Le, Saeed K Alzghari, Gary W. Jean, Ninh My La-Beck · 2017 · Therapeutics and Clinical Risk Management
  4. 1-Methyl-D-Tryptophan Potentiates TGF-β-Induced Epithelial-Mesenchymal Transition in T24 Human Bladder Cancer Cells
    Rodrigo Barbosa de Oliveira Brito, Camila Soares Malta, Diego Mota Souza, Luiz Henrique Gomes Matheus, Yves Silva Teles Matos, Chrisna Souza Silva, Janaína Mendes Ferreira, Valeria Sutti Nunes, Cristiane Miranda França, Humberto Dellê · 2015 · PLoS ONE
  5. Fragment-based approach to identify IDO1 inhibitor building blocks
    Alice Coletti, Francesca Camponeschi, Elisa Albini, Francesco Antonio Greco, Vincenzo Maione, Chiara Custodi, Federica Ianni, Ursula Grohmann, Ciriana Orabona, Francesca Cantini et al. · 2017 · European Journal of Medicinal Chemistry
  6. Tumor Associated Macrophages as Therapeutic Targets for Breast Cancer
    Liyan Lao, Siting Fan, Erwei Song · 2017 · Advances in experimental medicine and biology
  7. Effects of 1-Methyltryptophan on Immune Responses and the Kynurenine Pathway after Lipopolysaccharide Challenge in Pigs
    Elisa Wirthgen, Winfried Otten, Margret Tuchscherer, Armin Tuchscherer, Grażyna Domańska, Julia Brenmoehl, Juliane Günther, Daniela Ohde, Werner Weitschies, Anne Seidlitz et al. · 2018 · International Journal of Molecular Sciences
  8. Therapeutic Associations Comprising Anti-PD-1/PD-L1 in Breast Cancer: Clinical Challenges and Perspectives
    Fanny Ledys, Laura Kalfeist, Loïck Galland, Emeric Limagne, Sylvain Ladoire · 2021 · Cancers
  9. Combined with interventional therapy, immunotherapy can create a new outlook for tumor treatment
    Tonglei Fang, Junyuan Xiao, Yiran Zhang, Haiyan Hu, Yueqi Zhu, Yingsheng Cheng · 2021 · Quantitative Imaging in Medicine and Surgery
  10. Metabolic Modulation of Kynurenine Based on Kynureninase-Loaded Nanoparticle Depot Overcomes Tumor Immune Evasion in Cancer Immunotherapy
    Se-Youl Chae, Hojeong Shin, J.I. Woo, Seounghun Kang, Soo Min Lee, Dal‐Hee Min · 2024 · ACS Applied Materials & Interfaces
  11. Bioinformatic identification of differentially expressed genes associated with prognosis of locally advanced lymph node-positive prostate cancer
    Anna V. Kudryavtseva, Elena Lukyanova, Sergey Kharitonov, K. М. Nyushko, Alexey A. Krasheninnikov, Elena A. Pudova, Zulfiya G. Guvatova, B. Yа. Alekseev, Marina V. Kiseleva, А. Д. Каприн et al. · 2018 · Journal of Bioinformatics and Computational Biology
  12. The effects of aging on host resistance and disease tolerance to SARS‐CoV‐2 infection
    Darren Z. L. Mok, Candice Yuen Yue Chan, Eng Eong Ooi, Kuan Rong Chan · 2020 · FEBS Journal
  13. Not Only Immune Escape—The Confusing Role of the TRP Metabolic Pathway in Carcinogenesis
    Iwona Kwiatkowska, Justyna Magdalena Hermanowicz, Alicja Przybyszewska-Podstawka, Dariusz Pawlak · 2021 · Cancers
  14. Design, synthesis and biological evaluation of exiguamine A analogues as IDO1 inhibitors
    Junmin Dong, Xuan Pan, Ying Yang, Guangyan Zhang, Zhiyan Xiao, Zhanzhu Liu · 2021 · European Journal of Medicinal Chemistry
  15. Harnessing sulfur-doped carbon nanodots conjugated with IDO inhibitors act as a dual-mode breast cancer immunotherapy
    Roberta Cillari, Rita C. Acúrcio, Andreia Pereira Barateiro, Helena F. Florindo, Nicolò Mauro, Gennara Cavallaro · 2025 · Journal of Controlled Release
  16. IDO1-Targeted Therapy Does Not Control Disease Development in the Eµ-TCL1 Mouse Model of Chronic Lymphocytic Leukemia
    Selcen Öztürk, Verena Kalter, Philipp M. Roessner, Murat Sünbül, Martina Seiffert · 2021 · Cancers
  17. The Janus-Faced Nature of Ido1 in Infectious Diseases: Challenges and Therapeutic Opportunities
    Francesco Antonio Greco, Alice Coletti, Emidio Camaioni, Andrea Carotti, Maura Marinozzi, Antimo Gioiello, Antonio Macchiarulo · 2015 · Future Medicinal Chemistry
  18. Neutropenia and docetaxel exposure in metastatic castration‐resistant prostate cancer patients: A meta‐analysis and evaluation of a clinical cohort
    Aurelia H. M. de Vries Schultink, Marie‐Rose B. S. Crombag, Erik D. van Werkhoven, Hans-Martin M. B. Otten, Andries Marinus Bergman, Jan H.M. Schellens, Alwin D. R. Huitema, Jos H. Beijnen · 2019 · Cancer Medicine
  19. Breast cancer and immunology: biomarker and therapeutic developments
    Cesar Augusto Santa-Maria, Sue Jung Park, Sarika Jain, William John Gradishar · 2015 · Expert Review of Anticancer Therapy
  20. Docking Studies and Molecular Dynamic Simulations Reveal Different Features of IDO1 Structure
    Francesco Antonio Greco, Answald Bournique, Alice Coletti, Chiara Custodi, Daniela Dolciami, Andrea Carotti, Antonio Macchiarulo · 2016 · Molecular Informatics
  21. The AHR–NRF2–JDP2 gene battery: Ligand–induced AHR transcriptional activation
    Kenly Wuputra, Wen‐Hung Hsu, Chia‐Chen Ku, Ya-Han Yang, Kung‐Kai Kuo, Fang‐Jung Yu, Hsin-Su Yu, Kyosuke Nagata, Deng‐Chyang Wu, Chao‐Hung Kuo et al. · 2025 · Biochemical Pharmacology
  22. Computational study on new natural compound inhibitors of indoleamine 2,3-dioxygenase 1
    Shanshan Jiang, Hui Li, Lianhua Piao, Zheng Gen Jin, Jingyi Liu, Sitong Chen, Luwei Lucy Liu, Yujie Shao, Sheng Zhong, Bo Wu et al. · 2020 · Aging
  23. Indoleamine 2,3-Dioxygenase Deletion to Modulate Kynurenine Pathway and to Prevent Brain Injury after Cardiac Arrest in Mice
    Aurora Magliocca, Carlo Perego, Francesca Motta, Giulia Merigo, Edoardo Micotti, Davide Olivari, Francesca Fumagalli, Jacopo Lucchetti, Marco Gobbi, Alessandra Mandelli et al. · 2023 · Anesthesiology
  24. MGP+ and IDO1+ tumor-associated macrophages facilitate immunoresistance in breast cancer revealed by single-cell RNA sequencing
    Kexin Chang, Yangchi Jiao, Bo Zhang, Lan Hou, Xiangmei He, Donghui Wang, Ruolei Li, Ruolei Li, Zhe Wang, Pengyu Fan et al. · 2024 · International Immunopharmacology
  25. Chemo-immunotherapy by nanoliposomal epacadostat and docetaxel combination to IDO1 inhibition and tumor microenvironment suppression
    Rahimeh Khoshkhabar, Mona Yazdani, Seyedeh Hoda Alavizadeh, Zahra Saberi, Leila Arabi, Mahmoud Reza Jaafari · 2024 · International Immunopharmacology
  26. Binding Properties of Different Categories of Ido1 Inhibitors: A Microscale Thermophoresis Study
    Francesco Antonio Greco, Alice Coletti, Chiara Custodi, Daniela Dolciami, Alessandro Di Michele, Andrea Carotti, Maura Marinozzi, Nina Schlinck, Antonio Macchiarulo · 2017 · Future Medicinal Chemistry
  27. Role of Indoleamine 2,3-Dioxygenase in Acute Myeloid Leukemia
    Philip T. Sobash, Ravindra B Kolhe, Nagla Abdel Karim, Achuta Kumar Guddati, Anand Jillella, Vamsi K Kota · 2020 · Future Oncology
  28. Preclinical PK investigation of a novel IDO1/TDO dual inhibitor—SHR9146 in mouse plasma and tissues by LC-MS/MS
    Mei Xiao, Kan Zhong, Li Guo, Wei Li, Xiaoli Wang, Zhenjun Qiu, Taijun Hang · 2023 · Frontiers in Oncology
  29. Overcoming Therapeutic Resistance by Targeting Cancer Inflammation
    Gregory Lawrence Beatty · 2016 · American Society of Clinical Oncology Educational Book
  30. Current therapeutic landscape for advanced gastroesophageal cancers
    Anthony Lopez, Kazuto Harada, Dılşa Mızrak Kaya, Jaffer A. Ajani · 2018 · Annals of Translational Medicine
  31. Computer‐aided drug design in new druggable targets for the next generation of immune‐oncology therapies
    Rita C. Acúrcio, Anna Scomparin, Ronit Satchi‐Fainaro, Helena F. Florindo, Rita Cardoso Guedes · 2018 · Wiley Interdisciplinary Reviews Computational Molecular Science
  32. Indoleamine 2,3-dioxygenase expression in the prognosis of the localized prostate cancer
    Janaína Mendes Ferreira, Humberto Dellê, Cleber Pinto Camacho, Robson José de Almeida, Sabrina T. Reis, Yves Silva Teles Matos, Amanda M. Ramos Lima, Kátia Ramos Moreira Leite, José Pontes‐Júnior, Miguel Srougi · 2020 · International Urology and Nephrology
  33. Natural products targeting the metabolism of amino acids: from discovery to synthetic development
    Hyun Su Kim, Ahmed H.E. Hassan, Kyuho Moon, Jaehoon Sim · 2025 · Natural Product Reports
  34. Indoleamine 2,3-dioxygenase 1 in cancer immunotherapy: from small-molecule inhibition to PROTAC-mediated degradation
    Xiuyun Li, Hao Meng, Hefeng Wang, Yujing Zhang, Wanpeng Yu · 2025 · Frontiers in Pharmacology
  35. Bacterial tryptophan metabolites in cancer and atherosclerosis: insights for a role in immune checkpoint inhibition
    Thijs Dormans, Jeffrey Kroon, Elena Rampanelli, Max Nieuwdorp, Nick van Es · 2025 · Essays in Biochemistry
  36. Immunotherapy in gastrointestinal stromal tumors: Current landscape and future horizons
    Stavros P. Papadakos, Alexandra Argyrou, Ioannis Karniadakis, Stamatina Vogli, Stamatios E Theocharis · 2025 · World Journal of Clinical Oncology
  37. Medikamentöse Tumortherapie in der Dermato-Onkologie
    Lucie Heinzerling, Anke Hartmann, Martina Hund, Gerold Schuler · 2013 · Springer eBooks
  38. Indoleamine 2,3-Dioxygenase Activity-Induced Acceleration of Tumor Growth, and Protein Kinases-Related Novel Therapeutics Regimens
    Ayşe Başak Engin, Atilla Engin · 2021 · Advances in experimental medicine and biology
  39. Design, synthesis and evaluation of tryptophan analogues as tool compounds to study IDO1 activity
    Nicholas J. Cundy, Roseanna K. Hare, Tina Tang, Andrew G. Leach, Thomas A. Jowitt, Omar Qureshi, John C. Gordon, Nicholas M. Barnes, Catherine Brady, Emma Lloyd Raven et al. · 2021 · RSC Chemical Biology
  40. Comprehensive analysis of the prognostic value and immunological role of IDO1 gene in pan-cancer
    Kaili Lin, Yongfeng Wang, Fangyu Liu, Taifu You, Xiongxiong Liu, Runzhang Liu, Zeyang Li, Chunyu Zhen, Yunxia Zhang, Xingguang Liu et al. · 2024 · European journal of medical research
  41. Design, Synthesis and Biological Evaluation of Novel 1,2,5-Oxadiazol-3- Carboximidamide Derivatives as Indoleamine 2, 3-Dioxygenase 1 (IDO1) Inhibitors
    Zhifeng Xia, Yanyang Nan, Chang Liu, Guangyu Lin, Kedan Gu, Cheng Chen, Weili Zhao, Dianwen Ju, Xiaochun Dong · 2020 · Anti-Cancer Agents in Medicinal Chemistry
  42. Metabolic Stress and Immunity: Nutrient-Sensing Kinases and Tryptophan Metabolism
    Johanna Maria Gostner, Dietmar Fuchs, Katharina Kurz · 2021 · Advances in experimental medicine and biology
  43. Checkpoint Blockade Immunotherapy for Glioblastoma
    Katherine A. Riccione, Patrick C. Gedeon, L. Sanchez-Perez, John Howard Sampson · 2017 · Elsevier eBooks
  44. Combining immunotherapies to treat non-small cell lung cancer
    Alessia Spagnuolo, Cesare Gridelli · 2019 · Expert Review of Respiratory Medicine
  45. Indoleamine 2,3-dioxygenase
    Michele Coluccia, Daniela Secci, Paolo Guglielmi · 2023 · Elsevier eBooks
  46. Vaccine Therapy and Immunotherapy for Pancreatic Cancer
    Lei Zheng, Elizabeth M. Jaffee · 2018 · Springer eBooks
  47. Role of Kynurenine Pathway in HIV/AIDS
    Jean‐Pierre Routy, Vikram Mehraj, Kishanda Vyboh · 2015 · Springer eBooks
  48. Targeting Leukemia Stem Cells and the Immunological Bone Marrow Microenvironment
    Cristina Maccalli, Sarah Kathleen Tasian, Sergio Rutella · 2019 · Resistance to targeted anti-cancer therapeutics
  49. Recent Advancements in Immunotherapy for the Treatment of Metastatic Breast Cancer
    B. Madhu Krishna, Pankaj Garg, Sravani Keerthi Ramisetty, Meera Nair, Sharad S. Singhal · 2025 · Cancer treatment and research
  50. Modulation of the Kynurenine Pathway: A New Approach for Treating Neurodegeneration
    Julia K. Banaszkiewicz, Anna Kukiełka, Elżbieta Kudyk, Łucja Justyna Walczak, Katarzyna Wicha-Komsta, Mariola Herbet, Iwona Piątkowska‐Chmiel, Grzegorz Nowicki, Carmen E. Mielnik, Tomasz Kocki · 2026 · Life
  51. Tryptophan metabolism in tumor immune escape: mechanisms, cellular crosstalk, and therapeutic opportunities
    Jingyun Chen, X L Wang, Meiheng Gong, Yufeng Wang, Tingting Yu · 2026 · Frontiers in Immunology
  52. Clinical Trials Targeting the Kynurenine Pathway
    Melanie Anne Sheen, Hatem H. Soliman · 2015 · Springer eBooks
  53. CD4 + T Cells Mediate Dendritic Cell Licensing to Promote Multi‐Antigen Anti‐Leukemic Immune Response
    Luis Gil‐de‐Gómez, Jane Mattei, Jessica Heejong Lee, Stephan A. Grupp, Gregor S. D. Reid, Alix Eden Seif · 2024 · Cancer Medicine
  54. IDO/TDO Inhibition in Cancer
    George C. Prendergast, William J. Malachowski, Arpita Mondal, Peggy Scherle, Alexander J. Muller · 2017 · Springer eBooks
  55. Overview of Tumor Immunotherapy based on Indoleamine 2,3 Dioxygenase Inhibitors
    Xiangyu Hao · 2020 · International Conference on Biomedical and Bioinformatics Engineering (ICBBE)
  56. Checkpoint inhibition in the fight against cancer: NK cells have some to say in it
    Christian Sordo‐Bahamonde, Seila Lorenzo‐Herrero, Ana Pilar González, Segundo R. Gonzalez · 2021 · Elsevier eBooks
  57. Tackling Immune Targets for Breast Cancer Beyond PD-1PD-L1 Axis
    Yasser Tabana, Isobel Okoye, Arno G. Siraki, Shokrollah Elahi, Khaled Barakat · 2021 · Vide Leaf, Hyderabad eBooks
  58. Immunothérapie anticancer : les molécules immunomodulatrices en développement clinique
    Delphine Loirat, Christophe Le Tourneau · 2015 · ONCOLOGIE
  59. Immune Checkpoint Combinations with Inflammatory Pathway Modulators
    Nicholas C. DeVito, Michael A. Morse, Brent Allen Hanks, Jeffery M. Clarke · 2017 · Current cancer research
  60. Immune Checkpoint Inhibitors in Gastrointestinal Malignancies
    Christos K Fountzilas, Sunyoung S. Lee, Renuka V. Iyer, Patrick McKay Boland · 2018 · Elsevier eBooks
  61. Translating immune characteristics of metastatic tumors into therapeutic targets for cervical cancer
    Anne Marijne Heeren · 2018 · Digital Academic REpository of VU University Amsterdam (Vrije Universiteit Amsterdam)
  62. Towards the development of HAGE-based vaccines for the treatment of patients with triple negative breast cancers
    Divya Nagarajan · 2018 · Nottingham Trent University's Institutional Repository (Nottingham Trent Repository)
  63. Immunotherapy Landscape in Prostate Cancer: Successes, Failures and Promises
    Sabeeh-ur-Rehman Butt, Muhammad Saleem Iqbal Khan, Carmen Murias, Maria Reyes Gonzalez-Exposito, Hendrik‐Tobias Arkenau, Anna Patrikidou · 2019 · annals of urologic oncology
  64. Vaccine Therapy and Immunotherapy for Pancreatic Cancer
    Lei Zheng, Elizabeth M. Jaffee · 2017 · Springer eBooks
  65. Melanom
    Lucie Heinzerling, Anke Hartmann, Martina Hund · 2019 · Springer eBooks
  66. Faculty Opinions recommendation of Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden.
    Warren Allen Chow · 2018 · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature
  67. Estratégias vacinais voltadas para o controle de tumores associados ao HPV-16: efeitos da associação de 1-metil-triptofano e melatonina na redução da imunossupressão tumoral e potencialização de uma vacina de DNA capaz de ativar linfócitos T CD8+ citotóxicos.
    Patrícia da Cruz Souza · 2019
  68. Immunotherapy and Cancer Stem Cells
    Ravi Teja Chitturi Suryaprakash, Mohammad Ayman Abdulkarim Safi, Noufa Afri Alonazi, Ahdab A. Alsieedi, Omar Kujan · 2023 · BENTHAM SCIENCE PUBLISHERS eBooks
  69. THE RISE, FALL, AND FUTURE PROMISE OF IDO1 INHIBITORS FOR IMMUNO-ONCOLOGY
    Emily C. Cherney, David K. Williams, Liping Zhang, Susheel J. Nara · 2023 · Medicinal chemistry reviews
  70. Expression of indoleamine-2,3-dioxygenase 1 in sebaceous glands and related tumors of the eyelid: a potential diagnostic target
    Jan P. Ulloa-Padilla, Narmien Murdock, Cat N. Burkat, Alexander J. Müller, Lisa D. Laury-Kleintop, Raul Hernandez Rubio, Jacqueline R. Carrasco, Kenneth E. Morgenstern · 2025 · Orbit
  71. Additional file 1 of Comprehensive analysis of the prognostic value and immunological role of IDO1 gene in pan-cancer
    Lin, Kaili, Wang, Yongfeng, Liu, Fangyu, Taifu You, Liu, Xiongxiong, Runzhang Liu, Li, Zeyang, Zhen, Chunyu, Zhang, Yunxia, Xingguang Liu et al. · 2024 · Figshare
  72. Additional file 2 of Comprehensive analysis of the prognostic value and immunological role of IDO1 gene in pan-cancer
    Lin, Kaili, Wang, Yongfeng, Liu, Fangyu, Taifu You, Liu, Xiongxiong, Runzhang Liu, Li, Zeyang, Zhen, Chunyu, Zhang, Yunxia, Xingguang Liu et al. · 2024 · Figshare
  73. Optimisation immunologique et thérapeutique des doublets de chimio-immunothérapie dans le cancer du sein triple négatif
    Laura Kalfeist · 2024 · theses.fr (ABES)
  74. Caractérisation du microenvironnement tumoral dans le lymphome de Hodgkin classique par technologie spatiale in situ : identification de sous groupes tumoraux et implications thérapeutiques
    Barbara Burroni · 2025
  75. Neuroimaging of indoleamine 2,3-dioxygenase 1 (Ido1) in Alzheimer's disease: Development of a novel 18F-labeled PET tracer
    Hua Cheng, Nilay S. Narayan, Yongle Wang, Yanli Wang, Yafei Huang, Hongzhi Yang, Ramya Tokala, Jinwu Yan, Joseph W. Downey, Anne Siewko et al. · 2026 · Materials Today Bio
  76. BindingDB Entry 50014283: Design, synthesis and biological evaluation of exiguamine A analogues as IDO1 inhibitors.
    BindingDB · 2022 · UC San Diego
  77. BindingDB Entry 50011763: Design, synthesis and biological evaluation of indole-2-carboxylic acid derivatives as IDO1/TDO dual inhibitors.
    BindingDB · 2022 · UC San Diego
  78. BindingDB Entry 50014490: Discovery of indoximod prodrugs and characterization of clinical candidate NLG802.
    BindingDB · 2022 · UC San Diego
  79. BindingDB Entry 50019139: Recent advances in small molecule based cancer immunotherapy.
    BindingDB · 2024 · UC San Diego
  80. BindingDB Entry 50001412: Fragment-based approach to identify IDO1 inhibitor building blocks.
    BindingDB · 2020 · UC San Diego